stockportfolio.pro
Stocks / BIIB vs RGEN
BIIB vs RGEN
Biogen Inc. and Repligen Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Biogen Inc. (BIIB) | Repligen Corporation (RGEN) | |
|---|---|---|
| Market cap | $29.4B | $7.4B |
| Revenue (latest FY) | $9.89B | $738.26M |
| Net income (latest FY) | $1.29B | $48.89M |
| Revenue growth (5y CAGR) | -6.0% | 15.0% |
| Net margin | 13.1% | 6.6% |
| Return on equity | 7.1% | 2.3% |
| P/E ratio | 21.4 | 144.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIIB — free Open RGEN — freeFrequently asked questions
Which is bigger, BIIB or RGEN?
Biogen Inc. is larger by market capitalization — $29.4B versus $7.4B.
Which grows faster, BIIB or RGEN?
Over the last five fiscal years, Repligen Corporation grew revenue faster — 15.0%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.